EBNA1 sequence variations in four groups of lymphoma.

<p>The numbers across the top correspond to the amino acid positions under which the B95-8 prototype amino acid and nucleotide sequence are listed. Different patterns are noted to the left column, while the specimens showing identical sequences to each other are listed by a representative isolate in the second column. The followed numbers in the parentheses denote the amount of the identical sequences from NK/T, HL, DLBCL, and T cell lymphoma, respectively. The small letters denote the nucleotide, and the amino acids are denoted by capital letters. NK: nasal natural killer/T cell lymphoma; HL: Hodgkin’s lymphoma; DL: diffuse large B cell lymphoma; T: T cell lymphoma. Some rare sporadic mutations are not shown in Fig 1.</p

The distribution of EBNA1variants and EBV types in lymphomas, nasopharyngeal carcinomas, EBVaGCs and throat washing samples from healthy donors.

<p>NPCs: nasopharyngeal carcinomas; EBVaGCs: EBV-associated gastric carcinomas; TWs: throat washings from healthy donors.</p><p>The distribution of EBNA1variants and EBV types in lymphomas, nasopharyngeal carcinomas, EBVaGCs and throat washing samples from healthy donors.</p

Additional file 1: Figure S1. of Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity

All mice groups showed no significant difference in freezing time of training phase of fear conditioning (one-way ANOVA, F = 8.564, n = 42, p = 0.110). Data are plotted as mean ± standard error of the mean for each group (n = 6 per group). (PDF 143 kb

The distribution of EBNA1 variants and EBV types in NK/T, HL, DLBCL and T cell lymphoma.

<p>NK/T: natural killer/T cell lymphoma. HL: Hodgkin's lymphoma. DLBCL: diffuse large B cell lymphoma; T: T cell lymphoma.</p><p>The distribution of EBNA1 variants and EBV types in NK/T, HL, DLBCL and T cell lymphoma.</p

The basal levels of the RSNA, SAP and HR before the antigen injection.

<p>RSNA; renal sympathetic nerve activity, SAP; systemic arterial pressure, HR; heart rate, Values are expressed as means <u>+</u>SE.</p>a<p>; P<0.05 vs. the pentbabital rats.</p>b<p>; P<0.05 vs. the urethane rats.</p>c<p>; P<0.05 vs. the consious rats.</p><p>The basal levels of the RSNA, SAP and HR before the antigen injection.</p

RSNA and HR responses to hypotension with an intravenous injection of SNP in conscious and anesthetized rats.

<p>RSNA (A) and HR (B) responses to the decrease in blood pressure (−20, −40 and −60 mmHg) induced by the SNP injections in the conscious rats (black bar, n = 5) and the rats anesthetized with pentobarbital sodium (white bar, n = 6), urethane (vertical-striped bar, n = 6) or ketamine-xylazine (black bar with white diamond, n = 6). Values are expressed as the mean <u>+</u>SEM. N.D.; data were not obtained because SAP did not decrease by 60 mmHg in conscious rats. #P<0.05 vs. the conscious rats.</p

Sympathetic and hemodynamic responses to anaphylaxis in conscious and anesthetized rats.

<p>Representative recordings of RSNA, SAP and HR after an intravenous injection of the antigen, ovalbumin, into a sensitized conscious rat (A) and a sensitized rat under anesthesia with pentobarbital (B), urethane (C) or ketamine-xylazine (D).</p

Additional file 1 of An ovalbumin fusion strategy to increase recombinant protein secretion in chicken eggs

Additional file 1: Supplemental Fig. 1. Ovalbumin-EGFP fusion protein structures predicted by alphafold2 software. A. Structure of ovalbumin-EGFP fusion proteins with GS linker. B. Structure of ovalbumin-EGFP fusion proteins with (GS)3 linker. A. Structure of ovalbumin-EGFP fusion proteins with 32aa linker. A. Structure of ovalbumin-EGFP fusion proteins with (EAAAK)5 linker. Supplemental Fig. 2. Plasmids used in OVAL gene modified or CAG-EGFP chicken. A. Structure of CRISPR/Cas9 and donor plasmid used in ovalbumin locus site-specific gene integration. B. PiggayBac plasmid used in CAG-EGFP transgene chicken. Supplemental Fig. 3. EGFP fluorescence detection of PGCs derived from CAG-EGFP chicken. Supplemental Fig. 4. mCherry fluorescence detection of eggs from OVAL-E3-EGFP chicken. Supplemental Fig. 5. Immune fluorescence (IF) analysis of oviduct tissues from WT three-yellow chicken, CAG-EGFP chicken, and OVAL-E3-EGFP chicken. A. Ovalbumin antibody IF analysis of oviducts from WT three-yellow chicken, CAG-EGFP chicken, and OVAL-E3-EGFP chicken. B. EGFP antibody IF analysis of chicken oviduct from OVAL-E3-EGFP chicken. Supplemental Fig. 6. EGFP immune fluorescence analysis of oviduct tissues from wild type three-yellow chicken and CAG-EGFP chicken. Supplemental Fig. 7. FACS of EGFP+/EGFP- cells from OVAL-E3-EGFP chicken oviducts

Controllable Synthesis, Magnetic Properties, and Enhanced Photocatalytic Activity of Spindlelike Mesoporous α-Fe₂O₃/ZnO Core–Shell Heterostructures

Mesoporous spindlelike iron oxide/ZnO core–shell heterostructures are successfully fabricated by a low-cost, surfactant-free, and environmentally friendly seed-mediate strategy with the help of postannealing treatment. The material composition and stoichiometry, as well as these magnetic and optical properties, have been examined and verified by means of high-resolution transmission electron microscopy and X-ray diffraction, the thickness of ZnO layer can be simply tailored by the concentration of zinc precursor. Considering that both α-Fe₂O₃ and ZnO are good photocatalytic materials, we have investigated the photodegradation performances of the core–shell heterostructures using organic dyes Rhodamin B (RhB). It is interesting to find that the as-obtained iron oxides/ZnO core–shell heterostructures exhibited enhanced visible light or UV photocatalytic abilities, remarkably superior to the as-used α-Fe₂O₃ seeds and commercial TiO₂ products (P25), mainly owing to the synergistic effect between the narrow and wide bandgap semiconductors and effective electron–hole separation at the interfaces of iron oxides/ZnO

Fucoidan down-regulated VEGF expression in vivo.

<p>A) Representative photographs of the tumor sections examined by immunohistochemical staining for VEGF (×400 magnification). The assessment of VEGF was based on a cytoplasmic staining pattern. B) The tumors were harvested and assayed for VEGF protein by ELISA. The results are presented as mean ± SD (n = 7 tumors). Fucoidan caused significant reduction in intratumoral VEGF expression compared with control group. *<i>P</i><0.05 vs Control.</p